Skip to main content

Guide · Updated April 2026

GLP-1 Body Composition: What the Scale Doesn’t Tell You

GLP-1 body composition data shows the scale hides what matters. On tirzepatide (Mounjaro, Zepbound), a GLP-1/GIP dual agonist, about 34% of weight lost is lean mass. On semaglutide (Ozempic, Wegovy), the GLP-1 receptor agonist, that figure runs 39 to 45%. Scale weight alone cannot distinguish fat loss from muscle loss.

My scale said I lost 41 pounds in nine months on Mounjaro. My first DEXA scan said something different. Fat loss: 34 pounds. Lean mass loss: 7 pounds. Same 41 pounds on paper, two completely different stories underneath.

This is the part nobody prepares you for. The scale is a liar of omission. It tells you a real number, but it hides the mix. And the mix is everything for long-term results, metabolic rate, and whether you can actually keep the weight off after you stop.

This guide covers what the scale misses, what the clinical trials found on tirzepatide and semaglutide, what my DEXA scans showed across three data points, and how to track what matters.

Why the scale hides the real story

A pound is a pound, but not all pounds leave the body equally. When you lose weight on any intervention, diet, surgery, or medication, some percentage comes from fat and some from lean mass. Lean mass includes muscle, bone, organs, and water. Muscle is the part you want to keep.

The ratio matters because muscle burns more calories at rest than fat. Muscle also controls glucose disposal, grip strength, injury risk, and how you look at a given body weight. Two people at 180 pounds can look completely different depending on their fat-to-muscle ratio. The scale cannot see any of this.

On GLP-1 medications, the appetite suppression is strong enough that most users undereat protein and skip training. Both accelerate lean mass loss. If you do not measure body composition, you will not know this is happening until you plateau, stall, or regain weight after stopping.

What SURMOUNT-1 actually measured

SURMOUNT-1 (NEJM, July 2022, n=2,539) is the tirzepatide trial that produced the 22.5% average weight loss at 15mg. It also ran body composition substudies using DEXA. The finding most users never see: fat mass decreased 33.9% while lean mass decreased 10.9%.

That works out to roughly 34% of weight lost being lean tissue. Sounds bad in isolation, but it is better than most historical weight loss interventions. For context, bariatric surgery studies show 20 to 30% lean mass loss. Caloric restriction alone typically runs 25 to 35%. Tirzepatide is not worse than the baseline, it is slightly better on fat-to-lean ratio.

The second number that matters: the overall lean-to-fat ratio improved. Meaning by the end of the trial, participants had less muscle than they started with, but they had much less fat. The composition as a whole got leaner. That is the part pro-GLP-1 researchers emphasize.

What STEP 1 found on semaglutide

STEP 1 (NEJM, February 2021, n=1,961) is the semaglutide 2.4mg trial that produced 14.9% weight loss at 68 weeks. The body composition data here is less kind. Lean mass accounted for roughly 39 to 45% of total weight lost.

That is a meaningful gap versus tirzepatide. Semaglutide drives slightly more muscle loss per pound of weight loss. Part of this is likely the slower rate of weight loss with semaglutide (more time under the muscle-wasting stimulus), part is the lack of GIP agonism (GIP may have a protective effect on lean tissue).

If you are choosing between Ozempic and Wegovy versus Mounjaro and Zepbound, the body composition evidence favors the tirzepatide pair. Not by a huge margin, but by a real one. I covered this tradeoff in more detail in my fat loss vs weight loss guide.

Tirzepatide vs semaglutide: body composition at a glance

MetricTirzepatide (SURMOUNT-1)Semaglutide (STEP 1)
Average weight loss22.5% at 15mg14.9% at 2.4mg
Fat mass reduction33.9%Not reported identically
Lean mass reduction10.9%Higher per-pound
Lean mass share of total loss~34%~39 to 45%
Trial length72 weeks68 weeks
Sample size2,5391,961

The numbers are not directly comparable since the trials had different protocols and body comp substudies used slightly different methods. But the direction is clear. Tirzepatide preserves more lean mass per pound lost than semaglutide does.

Compare GLP-1 providers

Browse Provider Directory →

My DEXA data: three scans, one stubborn trend

I started tracking body composition three months into Mounjaro, not at baseline. I wish I had done a DEXA before starting. The pattern across my three scans at months 3, 6, and 9:

MetricMonth 3Month 6Month 9
Total weight223 lbs201 lbs182 lbs
Fat mass71 lbs54 lbs39 lbs
Lean mass147 lbs142 lbs138 lbs
Body fat %31.8%26.9%21.4%

Between months 3 and 9, I lost 41 pounds total. 32 pounds of that was fat. 9 pounds was lean mass. That is 22% of my loss coming from lean tissue, which is better than the SURMOUNT-1 average of 34%. The difference was protein and resistance training, not medication magic.

The months I stayed on top of both protein (180g+) and two weekly lifting sessions, lean mass loss slowed to near zero. The months I slipped on either one, the scan punished me. Protein intake on a GLP-1 is not optional if you want the body composition math to work.

I wrote a deeper breakdown in my DEXA scan after 6 months on Mounjaro post, which has the raw scan images.

Why lean mass loss compounds if you ignore it

Muscle is metabolically expensive tissue. Each pound burns roughly 6 to 10 calories per day at rest. Lose 10 pounds of muscle and your resting metabolic rate drops 60 to 100 calories per day. That sounds small until you stop the medication. Then appetite returns to baseline, but your burn rate is permanently lower than when you started. That is how the post-GLP-1 regain pattern works mathematically.

The STEP 4 trial followed semaglutide responders for 48 weeks after switching to placebo. They regained about two-thirds of lost weight within a year. Part of that was appetite rebound. Part was the lower metabolic floor created by lean mass loss. Users who preserved muscle during the loss phase regained less.

This is why GLP-1 exit strategy planning matters even before you start. If you do not defend lean mass during the loss phase, you cannot hold the loss after you stop. The math does not work.

The four things that protect body composition

Not a 10-item listicle. Four things actually move the needle:

  1. Protein at 0.8 to 1.0g per pound of goal body weight. For a 165 lb goal, that means 130 to 165g daily. Most GLP-1 users hit 60 to 90g without trying. Close the gap.
  2. Resistance training 2 to 3 times per week. Compound lifts: squat, deadlift, bench, row, overhead press. Cardio does not protect muscle, lifting does.
  3. Slower titration if body comp matters more than speed. Rapid weight loss correlates with higher lean mass loss. Staying at 5mg or 7.5mg tirzepatide longer gives the body time to adapt.
  4. Creatine 5g daily. Cheap, well-studied, supports strength and lean mass during caloric restriction. I covered the data in creatine on Ozempic and Mounjaro.

If you are already lifting and hitting protein, you are in the top 10% of GLP-1 users by body composition outcomes. That is not hyperbole, that is what the adherence data from structured programs suggests.

How to actually measure body composition

Five methods, ranked by accuracy:

MethodAccuracyCostAvailability
DEXA scanGold standard$45 to $150 per scanMost US metros
Hydrostatic weighingVery high$50 to $100Limited
BodPodHigh$40 to $75University labs
InBody / bioimpedanceModerateFree at gymsWidespread
Tape + calipersLowFreeAnywhere

DEXA is what I use. A single scan runs $45 to $80 at DexaFit locations in most major US cities. Schedule one at baseline before you start the medication, one at month 3, one at month 6, one at month 9. Four scans across a full loss cycle costs under $400 and gives you the only data that actually tells you what is happening.

InBody machines at gyms are free and trend reasonably well scan-to-scan on the same machine. Not accurate in absolute terms, but useful for tracking direction. Avoid switching between different InBody units if you use this approach. Our body composition calculator gives a rough estimate from tape measurements if you want a free starting point.

The scale still has a role

I am not saying to throw away the scale. I weigh myself daily. It is fast, free, and captures water and glycogen fluctuations that DEXA misses. The rule I follow: scale weight is a leading indicator, DEXA is the scorecard.

Weight dropping fast without resistance training means muscle is going with it. Weight dropping slower with consistent lifting and protein usually means the loss is cleaner. The scale still tells you something. It just cannot tell you the one thing that matters most.

Bottom line

The scale is a summary statistic. GLP-1 body composition data is the full report. On tirzepatide, expect roughly 34% of weight lost to be lean mass (10.9% reduction in SURMOUNT-1). On semaglutide, expect 39 to 45% (STEP 1). Protect muscle with protein at 1g per pound of goal weight, resistance training twice a week, and optional creatine. Track with DEXA quarterly, not the scale daily.

If you care about keeping the loss after stopping the medication, the body composition path is the only one that works long-term. Start with a provider who prescribes at a pace you can sustain, not the fastest pace possible. Compare GLP-1 providers to find one that supports a slower titration if that fits your goals.

FAQ

Is muscle loss on GLP-1s permanent?

Not if you rebuild it. Muscle is reactive tissue. With adequate protein and resistance training post-medication, lost muscle can come back. The harder part is rebuilding while appetite returns to baseline. See the GLP-1 maintenance guide for protocols.

How often should I get a DEXA scan on GLP-1s?

Every 3 months during the loss phase is enough. Scans cost $45 to $80 and you want enough gap between them to see real change. More frequent scanning adds noise without new information.

Does tirzepatide preserve muscle better than semaglutide?

The trial data suggests yes. SURMOUNT-1 showed roughly 34% of weight loss as lean mass versus 39 to 45% in STEP 1 for semaglutide. The dual GLP-1/GIP mechanism may help, and the faster fat loss rate shortens the period of caloric deficit.

Can I use my scale at home to track body composition?

Home smart scales with bioimpedance are directionally useful but not accurate in absolute terms. They read hydration and recent meals as much as body fat. Use them for trends on the same scale, not for absolute numbers.

Should I stop my GLP-1 if I am losing too much muscle?

Not necessarily. Add protein, add resistance training, and slow the dose titration before stopping. If lean mass loss continues after those fixes, a conversation with your prescriber about dose adjustment or pause makes sense. See our guide on what to do if your doctor will not adjust your dose.


Related

Guides:

Provider Reviews: Ro · Hims · MEDVi

Compare: All Providers · Best GLP-1 Programs · All Guides

Compare GLP-1 Providers →